SCHEMBL5500958

SCHEMBL5500958

Cc1cnc(Cl)c2c1oc1c(O)ccc(C(=O)O)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4A O75164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
KDM6B O15054 1/20 0.35
KDM6A O15550 1/20 0.35
TET3 O43151 1/20 0.35
KDM4B O94953 1/20 0.35
KDM5C P41229 1/20 0.35
KDM4D Q6B0I6 1/20 0.35
TET2 Q6N021 1/20 0.35
ALKBH5 Q6P6C2 1/20 0.35
TET1 Q8NFU7 1/20 0.35
FTO Q9C0B1 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
KDM2A Q9Y2K7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM3A Q9Y4C1 1/20 0.35
TTR P02766 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5505683 0.84 PDE4A (0.43) SMN1; SMN2KDM4ECA1CA2CLCN2
SCHEMBL5506611 0.80 PDE4A (0.40) LMNASMN1; SMN2KDM4EGAA
SCHEMBL73704 0.64 RAB9A (0.56) SMN1; SMN2KDM4EL3MBTL1CA1CA2
SCHEMBL11335559 0.62 CYP1A2 (0.46) KDM4ETTRCYP1A2MCL1
SCHEMBL30964013 0.62 GABRP (0.47) LMNASMN1; SMN2KDM4EGABRPGABRD
SCHEMBL18068216 0.62 GABRP (0.47) LMNASMN1; SMN2KDM4EGABRPGABRD
SCHEMBL29006242 0.61 CYP1A2 (0.68) SMN1; SMN2KDM4AKDM4EKDM6BKDM6A
SCHEMBL12476366 0.60 HAVCR2 (0.46) LMNASMN1; SMN2KDM4AKDM4EEGLN1
SCHEMBL31335879 0.60 CA1 (0.48) SMN1; SMN2KDM4ETTRCA1CA2
SCHEMBL1398470 0.60 CA1 (0.48) SMN1; SMN2KDM4ETTRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831227-A2 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS Glenmark Pharmaceuticals S.A. (CH) 2007-09-12 EP claimed
WO-2006064355-A2 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS GLENMARK PHARMACEUTICALS S.A. (US) 2006-06-22 WO claimed
EP-1831227-A2 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS Glenmark Pharmaceuticals S.A. (CH) 2007-09-12 EP disclosed
WO-2006064355-A2 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS GLENMARK PHARMACEUTICALS S.A. (US) 2006-06-22 WO disclosed